MatBA® for Mantle Cell Lymphoma
Mantle cell lymphoma (MCL) is an aggressive type of non-Hodgkins lymphoma that is particularly challenging to treat with a median overall survival of 3-4 years. Approximately 4,250 new cases of MCL are diagnosed annually in the U.S. There are four morphological variants (subtypes) of MCL: blastoid, pleomorphic, small cell and marginal zone-like. The blastoid and pleomorphic variants are clinically aggressive.
Initial diagnosis is largely based on cell morphology, immunophenotyping, and presenting clinical features. The primary genomic event in MCL is the t(11;14) chromosomal translocation. MCL is also typically characterized by the expression of CD5 and overexpression of Cyclin D1.
The MCL International Prognostic Index (MIPI) is the current tool used for prognosis in MCL and classifies patients into low, intermediate, and high risk groups. When determining risk stratification, MIPI takes into consideration four independent prognostic factors which include age, ECOG score, LDH level and white blood cell count. A biologic MIPI (MIPIb) includes these four prognostic factors as well as the Ki67 cell proliferation index.
Despite the MIPI and MIPIb, there are still considerable clinical differences within identical risk groups. More personalized means of prognosis are required to identify patients most likely to relapse after standard immune-chemotherapy.
In order to assist clinicians in the prognosis of MCL, CGI has developed the mature B-cell neoplasm array, also known as MatBA®-MCL. This assay is based on the detection of targeted gain/loss of genomic material associated with clinical outcome in MCL and can help in the clinical management of MCL.
MatBA®-MCL identifies information on nine distinct chromosomal regions, providing valuable prognostic data and critical information about the risk of progression of the disease.
|Reported Loci||Genomic Aberration|